Efficacy and safety of intravenous iron with different frequencies for renal anaemia: A systematic review and meta-analysis.
Study Goal
To evaluate the efficacy and safety of intravenous iron supplementation at different frequencies in patients with renal anaemia.
Results Summary
The study found no significant differences in efficacy or safety between low-frequency high-dose and high-frequency low-dose intravenous iron supplementation. A single dose or two doses were more cost-effective and patient-friendly.
Population
Patients with renal anaemia.
Effective Dosage
Low-frequency high-dose (1-2 doses, >200 mg/dose) and high-frequency low-dose (4-5 doses, ≤200 mg/dose).
Duration
Not specified.
Interactions
None mentioned.
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
intravenous iron supplementation | no change | increase in TSAT | patients with renal anaemia | WMD = 1.90; 95% CI = -2.04 to 5.84 | no significant differences | #1 |
intravenous iron supplementation | no change | allergies | patients with renal anaemia | - | share similar safety | #2 |
intravenous iron supplementation | no change | infections | patients with renal anaemia | - | share similar safety | #3 |
intravenous iron supplementation | no change | all-cause mortality | patients with renal anaemia | - | share similar safety | #4 |
intravenous iron supplementation | no change | cardiovascular events | patients with renal anaemia | - | share similar safety | #5 |
intravenous iron supplementation | no change | transfer saturation (TSAT) | patients with renal anaemia | - | share similar efficacy | #6 |
intravenous iron supplementation | no change | serum ferritin (SF) | patients with renal anaemia | - | share similar efficacy | #7 |
intravenous iron supplementation | no change | haemoglobin (HGB) | patients with renal anaemia | - | share similar efficacy | #8 |
a single dose or two doses of intravenous iron | neutral | - | patients with renal anaemia | - | are more cost-effective | #9 |
a single dose or two doses of intravenous iron | neutral | - | patients with renal anaemia | - | are more patient friendly | #10 |
WHAT IS KNOWN AND OBJECTIVE: To evaluate the efficacy and safety of intravenous iron supplementation in patients with renal anaemia. METHODS: We searched the PubMed, Embase, Cochrane Library, and Web of Science from their inception until 17 September 2021, for randomized controlled trials (RCTs) to evaluate the efficacy and safety of intravenous iron at different frequencies. The observed efficacy indicators included transfer saturation (TSAT), serum ferritin (SF) and haemoglobin (HGB). Outcomes of interest included allergies, infections, all-cause mortality and cardiovascular events. RESULTS AND DISCUSSION: Of the 751 eligible studies, 7 RCTs met the inclusion criteria. The RCTs showed that there were no significant differences between the low-frequency high-dose group (1-2 doses, >200 mg/dose) and the high-frequency low-dose group (4-5 doses, ≤200 mg/dose) in the increase in TSAT (WMD = 1.90; 95% CI = -2.04 to 5.84; I WHAT IS NEW AND CONCLUSION: Frequencies of intravenous iron supplementation with similar doses share similar safety and efficacy in patients with renal anaemia. However, a single dose or two doses of intravenous iron are more cost-effective and patient friendly. These findings may provide evidence for the clinical application of intravenous iron supplementation for patients with renal anaemia.